title: [Urinary incontinence: what's new in therapy?].
authors: Abteilung für Geriatrie und Frührehabililitation, HELIOS Hanseklinikum Stralsund.
authors: Klaus F
authors: KF
authors: Becher
authors: Institut für Biomedizin des Alterns, Friedrich-Alexander-Universität Erlangen-Nürnberg.
authors: Cornel C
authors: CC
authors: Sieber
mesh_terms: D000083:Acetanilides / Q000009:adverse effects / Q000627:therapeutic use; D000283:Administration, Intravesical; D000368:Aged; D001521:Behavior Therapy; D019274:Botulinum Toxins, Type A / Q000009:adverse effects / Q000627:therapeutic use; D018680:Cholinergic Antagonists / Q000009:adverse effects / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003299:Cooperative Behavior; D005260:Female; D006801:Humans; D033183:Interdisciplinary Communication; D008297:Male; D013844:Thiazoles / Q000009:adverse effects / Q000627:therapeutic use; D001743:Urinary Bladder / Q000187:drug effects / Q000503:physiopathology; D001750:Urinary Bladder, Neurogenic / Q000209:etiology / Q000503:physiopathology / Q000628:therapy; D053201:Urinary Bladder, Overactive / Q000209:etiology / Q000503:physiopathology / Q000628:therapy; D014549:Urinary Incontinence / Q000209:etiology / Q000503:physiopathology / Q000628:therapy*
chemical_list: D000083:Acetanilides; D018680:Cholinergic Antagonists; D013844:Thiazoles; D019274:Botulinum Toxins, Type A; C520025:mirabegron